GeNeuro SA

Chemin du Pré-Fleuri 3, Plan-Les-Ouates, Genève, Switzerland

Clinical Trials

17 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Phase 1

85.0%

Phase 2

15.0%

Trial Status Distribution

Active, not recruiting

85.0%

Completed

10.0%

Terminated

5.0%

Clinical Trials

Trials sponsored by this organization (20)

Temelimab as a Disease Modifying Therapy in Patients With Neuropsychiatric Symptoms in Post-COVID 19 or PASC Syndrome

Phase 2

Completed

interventional

Aug 2022203 participants

A clinical study to assess the long-term safety of GNbAC1 in patients with Multiple Sclerosis

Phase 1

Active, not recruiting

Jan 2021220 participants

Clinical study to assess efficacy, safety and pharmacokinetics of GNbAC1 in patients with relapsing remitting multiple sclerosis

Phase 1

Active, not recruiting

Feb 2018260 participants

A clinical study to assess the long-term safety of GNbAC1 in patients with Multiple Sclerosis

Phase 1

Active, not recruiting

Sep 2017240 participants

Assessing the HERV-W Env ANtagonist GNbAC1 for Evaluation in an Open Label Long-term Safety Study in Patients With Multiple Sclerosis

Phase 2

Terminated

interventional

Jun 2017220 participants

A clinical study to assess the long-term safety of GNbAC1 in patients with Multiple Sclerosis

Phase 1

Active, not recruiting

Apr 2017240 participants

A clinical study to assess the long-term safety of GNbAC1 in patients with Multiple Sclerosis

Phase 1

Active, not recruiting

Apr 2017240 participants

A clinical study to assess the long-term safety of GNbAC1 in patients with Multiple Sclerosis

Phase 1

Active, not recruiting

Mar 2017200 participants

Page 1 of 3

Approvals

No approval data available

News

No news articles found

Back to Organizations